

## Novo Nordisk Minnesota State Insulin Affordability Program Refill/Change Request Form

**Health Care Practitioner:** Use this form to request a refill, add a new medication, request a change in medication, change the dosage of a current medication, or to update your health care practitioner's contact information.

This form must be submitted directly by the HCP and must include a cover letter/HCP letterhead to clearly identify HCP as the sender.

Check all that apply:

Refill request New medication Medication change HCP address or information change Other

			*Asteri	sks indicate	required fi	eld. Do not leave blanl	
		Section J: Pa	tient Informat	ion			
Patient First Name*:		Patie	Patient Last Name*: DOB*:				
Known Drug Allergies*:							
Patient Street Address*:						_	
City*:		State*: ZIP*:					
Patient Email:							
S	ection	K: Health Car	e Practitioner I	[nformat	ion		
Licensed Health Care Provider	(All medic	ation is shipped to	patient's address. No	PO Box per	mitted.)		
Prescriber First Name*:			Prescriber Last Name*:				
Designation:							
Street Address*:							
Suite/Building/Floor#:							
City*:			State*:		ZIP*:	ZIP*:	
Phone*:		State License Nu	Number#*:		State W	State Where Licensed:	
Fax*:	Offi	ce Contact:		Office Email:			
NPI*:							

### Section L: Health Care Practitioner Declaration

Health Care Practitioner Declaration: "My signature certifies that I am a licensed health care practitioner eligible under state law to prescribe, receive, and dispense the requested medication(s) listed on the attached order, shipped from Novo Nordisk, and that I am not prohibited from participating in federally funded health care programs. If I am a Nurse Practitioner, Physician Assistant, Pharmacist, or PharmD, I certify that I am authorized and eligible in the state within which I am currently practicing to prescribe, receive, and dispense these products, and that I have my supervising Physician's approval to do so if required by law. Note: Prescribing practitioner information must match practitioner's signature. I also certify that the product(s) being prescribed are to treat diagnosis(es) consistent with indication(s) and dosing described in the product's prescribing information. I further certify that all information provided in the Licensed Health Care Practitioner Information section is correct. I agree that medication(s) provided to me by Novo Nordisk for the applicant named in the Applicant Information section will be provided by me to such eligible applicant for his or her own use without charge. I will not otherwise use any of such medications or prescribe, provide or dispense all or any portion thereof for the use of any other person. I consent that Novo Nordisk may contact the applicant named in the Applicant Information section for verification of applicant status and receipt of the indicated medication(s). I further consent that Novo Nordisk may, at its discretion and with adequate notice, perform an on-site audit/review solely related to Novo Nordisk Diabetes Patient Assistance Program (PAP) records related to the applicant named above on this application. I understand that I am not eligible to seek reimbursement for any medication dispensed by PAP, from any government program or third-party insurer and will not apply any Novo Nordisk medication, provided by PAP, towards the applicant's True-O

#### PLEASE DO NOT INCLUDE PATIENT MEDICAL RECORDS.

Phone: 866-310-7549 M-F 8am-8pm ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax: 866-441-4190

Fiasp®, FlexPen®, FlexTouch®, NovoFine®, Novolin®, NovoLog®, NovoPen Echo®, PenFill®, and Tresiba® are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S.



# Novo Nordisk Minnesota State Insulin Affordability Program Refill/Change Request Form

Patient First Name*:			Patient Last Name*:			DOB*:		
Prescriber First Name*:			Prescriber Last Name*:			NPI*:		
Product*  Max Dose/Da (units)		Sig/Direc	Sig/Directions* Formulation* Cart = Cartrid					Qty
Insulin				·				
Tresiba® (insulin degludec) injection U-100				Vial	Vial FlexTou			
Insulin Degludec Injection U-100 (UB)				Vial	Vial FlexT		Touch <sup>®</sup>	
Tresiba® (insulin degludec) injection U-200				Flex	FlexTouch®			
Insulin Degludec Injection U-200 (UB)				Flex	FlexTouch®			
<b>Fiasp</b> ® (insulin aspart) injection 100 U/mL				Vial	Flex	«Touch®	Cart	
NovoLog® (insulin aspart) injection 100 U/mL				Vial	Vial Flex		Cart	
Insulin Aspart Injection 100 U/mL (UB)				Vial	FlexPen®		Cart	
Novolin® R (insulin human) injection 100 U/mL				Vial	Vial			
Novolin® N (insulin isophane human) injectable suspension 100 U/mL				Vial	Vial			
NovoPen Echo®		1 pen						
<b>NovoLog® Mix 70/30</b> (insulin aspart protamine and insulin aspart) injectable suspension 100 U/mL				Vial	Flex	«Pen®		
Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 100 U/mL (UB)				Vial	Flex	«Pen®		
Novolin® 70/30 (insulin isophane human and insulin human) injectable suspension 100 U/mL				Vial				
Needles								
NovoFine® 32G 6mm (100 needles/box)								
FlexPen®/FlexTouch® are used with Novo Nordisk	disposable ne	eedles. <b>Ne</b>	edles will not be sent as p	part of the PAP	order if	they are r	ot reque	sted.

By signing below, I acknowledge that I have read and agree to the Health Care Practitioner Declaration on page 1. Products are dispensed as written. (Handwritten/valid electronic signatures accepted; no photocopies, power of attorney, or stamped signatures allowed.)

-	
7	
N	
-	

Practitioner Signature\*:

Date\*:

### PLEASE DO NOT INCLUDE PATIENT MEDICAL RECORDS.

Phone: 866-310-7549 M-F 8am-8pm ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax: 866-441-4190